FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:1762-1764 October 30, 2003 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by The Matisse Investigators Related Article by Francis, C. W. Related Article by Schulman, S. PubMed Citation

The seemingly magical transmutation of shed blood into a solid has fascinated inquisitive observers for millennia. Hippocrates, in De Carnibus, and Aristotle, in Meteorology, postulated that the phenomenon was due to cooling, and as late as the 1790s John Hunter suggested that exposure to air was the cause. In 1832, Johannes Müller identified the insoluble clot substance "fibrin," and Rudolf Virchow named its hypothetical soluble plasma precursor "fibrinogen." Fibrinogen was isolated by Prosper Sylvain Denis in 1856. Alexander Schmidt demonstrated that the transformation of fibrinogen into fibrin was a "fermentative" (enzymatic) process and named the fibrin ferment "thrombin"; he called . . . [Full Text of this Article]

Source Information

From the Department of Physiology, Jefferson Medical College, Philadelphia.

This article has been cited by other articles:

• Rettie, A. E., Tai, G. (2006). The Pharmocogenomics of Warfarin: Closing in on Personalized Medicine. Mol. Interv. 6: 223-227 [Abstract] [Full Text]  
• Hanley, J P (2004). Warfarin reversal. J. Clin. Pathol. 57: 1132-1139 [Abstract] [Full Text]  
• van Walraven, C. (2004). Ximelagatran was non-inferior to warfarin in preventing stroke and systemic embolism in atrial fibrillation. Evid. Based Med. 9: 43-43 [Full Text]  
• (2004). Preventing VTE with Ximelagatran. Journal Watch Cardiology 2004: 4-4 [Full Text]  
• (2004). Fondaparinux vs. IV Heparin for PE. Journal Watch Cardiology 2004: 5-5 [Full Text]